Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech, Inc. (Nasdaq: ONCY) is a clinical-stage biotechnology company whose news flow centers on the development of pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Company updates frequently highlight clinical data in metastatic pancreatic cancer, metastatic breast cancer, and gastrointestinal tumors such as anal and colorectal cancers, where pelareorep is being evaluated in combination with chemotherapy and checkpoint inhibitors.
News releases from Oncolytics often cover clinical trial milestones, including results from the GOBLET study in squamous cell anal carcinoma and colorectal cancer, as well as alignment with the U.S. Food and Drug Administration on pivotal trial designs in first-line metastatic pancreatic ductal adenocarcinoma. Investors can also expect announcements about planned registration-directed studies, accelerated approval strategies in indications with no FDA-approved therapies, and translational findings such as tumor-specific T-cell responses in KRAS-mutant metastatic colorectal cancer.
Oncolytics’ news also addresses corporate and regulatory developments, including its proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada, its transition to domestic issuer status under SEC rules, and capital markets activities such as at-the-market equity programs. Additional updates describe expansions of the company’s Gastrointestinal Tumor Scientific Advisory Board and appointments of senior leaders in strategy, operations, and biostatistics to support late-stage clinical execution.
This ONCY news page aggregates these press releases and related coverage so readers can follow key developments in pelareorep’s clinical progress, regulatory interactions, intellectual property initiatives, and corporate strategy. It is a useful resource for tracking how new data, advisory board input, and structural changes may influence the company’s oncology pipeline over time.
Oncolytics Biotech announced promising results from the phase 1/2 GOBLET study, demonstrating a 69% objective response rate (ORR) for first-line treatment of advanced pancreatic cancer, significantly outperforming the historical average of 25%. In total, 85% of patients showed a clinical benefit, with plans to advance to a pivotal study. The interim findings will be discussed in a key opinion leader webinar on November 14, 2022. The GOBLET study highlights the potential of pelareorep when combined with atezolizumab and chemotherapy, showing encouraging results for pancreatic cancer treatment.
Oncolytics Biotech reported significant interim data from its GOBLET trial, revealing a 70% objective response rate (ORR) for pancreatic cancer, nearly triple the historical average of 25%. The company holds $32.4 million in cash, projected to fund operations through 2023. They plan further studies for both pancreatic and breast cancer treatments, aiming for pivotal trials, with impactful results expected from their BRACELET-1 trial in early 2023. Despite a net loss of $4.4 million for Q3 2022, losses are down from $4.9 million during the same period last year.
Oncolytics Biotech reported interim results from the phase 1/2 GOBLET study for advanced pancreatic ductal adenocarcinoma, showing a 70% objective response rate (ORR), nearly three times higher than the average 25% from historical trials. The data indicates that pelareorep enhances the efficacy of PD-(L)1 inhibitors combined with standard chemotherapy. The company plans to engage regulators regarding expedited approval and will further discuss these findings in their upcoming earnings call.
Oncolytics Biotech announced a conference call on November 7, 2022, at 8:30 a.m. ET, to discuss its third-quarter financial results and corporate updates. The call will focus on the performance of pelareorep, an immunotherapeutic agent in development for various cancers, including its upcoming registration study in metastatic breast cancer. Interested parties can participate via a dial-in number or a webcast available on the company's Investor Relations page.
Further details and a replay option are provided in the press release.
Oncolytics Biotech Inc. (NASDAQ: ONCY) has appointed Jonathan Rigby to its Board of Directors. Rigby, with over 30 years in the pharmaceutical sector, previously served as CEO of Revolo Biotherapeutics and led SteadyMed through its NASDAQ listing. His experience is expected to aid Oncolytics in advancing its cancer therapeutic, pelareorep, which has shown potential in late-stage trials for breast and pancreatic cancers. The company anticipates valuable data readouts that may propel pelareorep towards registration, enhancing its partnerships within the biopharmaceutical industry.
Oncolytics Biotech announced key developments in their clinical trials, notably the full enrollment of the Phase 2 BRACELET-1 trial focused on HR+/HER2- breast cancer and success in the pancreatic cancer cohort of the GOBLET trial, achieving partial responses in all Phase 1b patients.
They reported $33.7 million in cash as of June 30, 2022, providing a financial runway into late 2023. The management highlighted pelareorep's potential to enhance cancer treatment outcomes. A conference call is scheduled today for further details.
Oncolytics Biotech (NASDAQ: ONCY) announced a conference call on August 11, 2022, at 8:30 a.m. ET to discuss Q2 financial results and corporate updates. Pelareorep, its lead therapeutic agent, is under evaluation in clinical trials targeting various cancers, including metastatic breast cancer. The company emphasizes the potential of pelareorep in enhancing immune responses and its synergy with other oncology treatments. However, risks such as funding availability and the efficacy of pelareorep may impact future outcomes.
Oncolytics Biotech has announced positive results from the phase 1b portion of its GOBLET study for pancreatic cancer, showing partial responses in all patients (n=3). The study evaluated pelareorep combined with chemotherapy and an anti-PD-L1 checkpoint inhibitor, meeting the criteria for expansion to additional patients. An independent review reported no toxicity concerns, suggesting potential for improved treatment approaches in pancreatic cancer, which has limited standard treatment efficacy. The findings will be featured at the ESMO World Congress on Gastrointestinal Cancer.
Oncolytics Biotech Inc. (NASDAQ: ONCY) held its Annual General Meeting (AGM) on June 16, 2022, with a shareholder turnout of 40.43%. James T. Parsons was elected to the Board of Directors, replacing Leonard Kruimer who did not seek re-election. Mr. Parsons, a seasoned executive with over 20 years in the life sciences sector, previously served as CFO at Trillium Therapeutics before its acquisition by Pfizer for $2.2 billion. The meeting also approved all resolutions, including the number of directors and the appointment of auditors for the upcoming year.
Oncolytics Biotech (NASDAQ: ONCY) has announced that Dr. Matt Coffey, President and CEO, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on May 18, 2022, at 11:00 a.m. ET. The conference will be held at the InterContinental New York Barclay. A live webcast of the presentation will be available on the company’s Investor Relations page and archived until August 15, 2022. Oncolytics is developing pelareorep, an immunotherapeutic agent aimed at treating various cancers.